Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.31 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.31 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.31 |
| ▸ | ACE | P12821 | 2/20 | 0.31 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22029854 | 1.00 | ATM (0.44) | ATMCYP2C19GABRR1CYP1A2CYP2D6 | |
| SCHEMBL6270654 | 1.00 | ATM (0.44) | ATMCYP2C19GABRR1CYP1A2CYP2D6 | |
| SCHEMBL26118356 | 0.85 | ATM (0.40) | ATM | |
| SCHEMBL26120685 | 0.85 | ATM (0.40) | ATM | |
| SCHEMBL26116981 | 0.82 | ATM (0.42) | ATM | |
| SCHEMBL584116 | 0.80 | NOTUM (0.35) | ATMACEMAPT | |
| SCHEMBL8273881 | 0.79 | ATM (0.39) | ATMACEAGTR2 | |
| SCHEMBL28506529 | 0.79 | HPGD (0.46) | ATMACE | |
| SCHEMBL2901536 | 0.78 | — | — | |
| SCHEMBL3222636 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3490994-B1 | SPIRO-LACTAM AND BIS-SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | APTINYX INC (US) | 2024-02-07 | — | — | EP | disclosed |
| CN-109661398-B | Spiro-lactam and di-spiro-lactam NMDA receptor modulators and uses thereof | 阿普廷伊克斯股份有限公司 | 2022-07-05 | — | — | CN | disclosed |
| US-11028095-B2 | Spiro-lactam and bis-spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-20200181159-A1 | SPIRO-LACTAM AND BIS-SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2020-06-11 | — | — | US | disclosed |
| EP-1572183-A1 | ALPHA-2-DELTA LIGAND FOR THE TREATMENT OF SEXUAL DYSFUNCTION | Warner-Lambert Company LLC (US) | 2005-09-14 | — | — | EP | disclosed |
| EP-1558246-A1 | PROLINE DERIVATIVES HAVING AFFINITY FOR THE CALCIUM CHANNEL ALPHA-2-DELTA SUBUNIT | Pfizer Limited (GB) | 2005-08-03 | — | — | EP | disclosed |
| WO-2004054563-A1 | ALPHA-2-DELTA LIGAND FOR THE TREATMENT OF SEXUAL DYSFUNCTION | WARNER-LAMBERT COMPANY LLC (US) | 2004-07-01 | — | — | WO | disclosed |
| WO-2004039367-A1 | PROLINE DERIVATIVES HAVING AFFINITY FOR THE CALCIUM CHANNEL ALPHA-2-DELTA SUBUNIT | PFIZER LIMITED (GN) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200181159-A1 | SPIRO-LACTAM AND BIS-SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN2C | ATM 2237/4885CYP2C19 909/4885GABRR1 114/4885 |
| US-11028095-B2 | Spiro-lactam and bis-spiro-lactam NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN2C | ATM 2237/4885CYP2C19 909/4885GABRR1 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.